Treatment of nonalcoholic steatohepatitis with probiotics
Background and aims: Gut microbiota is involved in energy harvesting and systemic inflammation. Probiotics ameliorate nonalcoholic steatohepatitis (NASH) in animal studies. We aimed to test the efficacy of probiotics treatment and study the gut microbiota composition of humans with NASH.
Methods: Patients with biopsy-confirmed NASH were randomized to receive probiotics (including 4 Lactobacillus strains and Bifidobacterium bifidum; 10 subjects) or usual care (10 subjects) for 6 months. The primary endpoint was change in hepatic triglyceride content as measured by proton-magnetic resonance spectroscopy. Gut microbiota of NASH subjects was compared to control subjects matched for age, gender and body mass index, and was assessed serially during treatment. Analysis was performed by pyrosequencing of 16S rRNA genes from fresh morning stool samples (454 Life Sciences, Branford, CT).
Results: Hepatic triglyceride content decreased by a median of 7.6% (IQR -11.5%, -0.2%) in the probiotics group (P=0.028) and increased by 0.9% (IQR -4.2%, 2.4%) in the usual care group (P=0.80). The probiotics group tended to have greater reductions in serum alanine aminotransferase (-20 IU/l vs. 10 IU/l; P=0.44), aspartate aminotransferase (-7 IU/l vs. 11 IU/l; P=0.11) and gamma-glutamyl transpeptidase (-6 IU/l vs. 14 IU/l; P=0.28) than the usual care group. The change in body mass index and other metabolic parameters did not differ between the two groups. Analysis of 8 NASH subjects and 6 controls yielded 1,287,850 partial bacterial 16S rRNA sequences. Compared to controls, NASH subjects had higher relative abundance of Bacteroides (87.8% vs. 80.8%), but lower abundance of Firmicutes (10.3% vs. 13.5%) and Fusobacterium (0.27% vs. 3.9%) (all P<10-6). Probiotics reduced the abundance of Bacteroides (92.1% to 89.1%; P<10-6) and increased the abundance of Firmicutes (6.6% to 9.4%; P<10-6), but the change was not observed in the usual care group.
Conclusions: Probiotics treatment reduces hepatic triglyceride content in patients with NASH. Altered gut microbiota is associated with NASH, and may be modified by probiotics. Our results support further evaluation of probiotics as a treatment for NASH in larger clinical trials. (ClinicalTrials.gov number, NCT00870012)
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.